Table 3 |
||||
|
Univariate analysis of 30-day outcome of ICH among patients with hematological malignancies. |
||||
|
Alive (n = 26) |
Dead (n = 46) |
Univariate analysis, P value |
Multivariate analysis, P value (odds ratio; 95% CI) |
|
|
|
||||
|
Gender: |
0.604 |
|||
|
Male |
16 |
32 |
||
|
Female |
10 |
14 |
||
|
Age |
>0.999 |
|||
|
≥60 years |
12 |
20 |
||
|
<60 years |
14 |
26 |
||
|
Hematological malignancies |
0.679 |
|||
|
AML |
14 |
29 |
||
|
APL |
5 |
4 |
||
|
ALL |
2 |
3 |
||
|
Lymphoma |
3 |
4 |
||
|
Myeloma |
2 |
6 |
||
|
Remission status |
0.448 |
|||
|
Yes |
4 |
4 |
||
|
No |
22 |
42 |
||
|
Post HSCT |
0.473 |
|||
|
Yes |
2 |
7 |
||
|
No |
24 |
39 |
||
|
Underlying hypertension |
>0.999 |
|||
|
Yes |
7 |
12 |
||
|
No |
19 |
34 |
||
|
Sepsis |
0.050 |
|||
|
Yes |
8 |
26 |
||
|
No |
18 |
20 |
||
|
CNS involvement |
>0.999 |
|||
|
Yes |
2 |
4 |
||
|
No |
24 |
42 |
||
|
Subarachnoid hemorrhage |
0.007 |
0.021 (10.9; 1.3 to 88.9) |
||
|
Yes |
1 |
14 |
||
|
No |
25 |
32 |
||
|
Multifocal hemorrhage |
0.006 |
0.026 (4.7; 1.6 to 14.0) |
||
|
Yes |
6 |
27 |
||
|
No |
20 |
19 |
||
|
Surgical intervention |
0.085 |
|||
|
Yes |
7 |
4 |
||
|
No |
19 |
41 |
||
|
Leukocyte count |
>0.999 |
|||
|
≥100,000 cells/μl |
4 |
8 |
||
|
<100,000 cells/μl |
22 |
38 |
||
|
Platelet count |
0.802 |
|||
|
≥20,000 cells/μl |
16 |
30 |
||
|
<20,000 cells/μl |
10 |
16 |
||
|
Prolongation of prothrombin time |
0.013 |
0.008 (10.9; 1.3 to 85.5) |
||
|
INR ≥1.5 |
1 |
14 |
||
|
INR <1.5 |
24 |
32 |
||
|
|
||||
|
ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; APL = acute promyelocytic leukemia; CNS = central nervous system; HSCT = hematopoietic stem cell transplantation; ICH = intracranial hemorrhage; INR = international normalized ratio. |
||||
|
Chen et al. BMC Medicine 2012 10:97 doi:10.1186/1741-7015-10-97 |
||||
